These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1023 related items for PubMed ID: 34705268

  • 21. Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis.
    McKinley BJ, Pai TS, Wolf EB, Li S, Correia GSC, Zhao Y, Manochakian R, Lou Y.
    Front Oncol; 2024; 14():1417175. PubMed ID: 38974234
    [Abstract] [Full Text] [Related]

  • 22. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ, Zhu HH, Liu YT, Lin L, Xing PY, Hao XZ, Cong MH, Wang HY, Wang Y, Li JL, Feng Y, Hu XS.
    Zhonghua Zhong Liu Za Zhi; 2022 May 23; 44(5):416-424. PubMed ID: 35615798
    [Abstract] [Full Text] [Related]

  • 23. Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
    Inomata M, Matsumoto M, Hayashi K, Seto Z, Hirai T, Tokui K, Taka C, Okazawa S, Kambara K, Imanishi S, Miwa T, Hayashi R, Matsui S, Tobe K.
    Anticancer Res; 2023 Jul 23; 43(7):3241-3246. PubMed ID: 37351972
    [Abstract] [Full Text] [Related]

  • 24. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
    Kuribayashi T, Ohashi K, Nishii K, Ninomiya K, Tsubata Y, Ishikawa N, Kodani M, Kanaji N, Yamasaki M, Fujitaka K, Kuyama S, Takigawa N, Fujimoto N, Kubota T, Inoue M, Fujiwara K, Harita S, Takata I, Takada K, Okawa S, Kiura K, Hotta K.
    J Cancer Res Clin Oncol; 2024 Feb 12; 150(2):89. PubMed ID: 38347279
    [Abstract] [Full Text] [Related]

  • 25. Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings.
    Yoneda T, Sone T, Koba H, Shibata K, Suzuki J, Tani M, Nishitsuji M, Nishi K, Kobayashi T, Shirasaki H, Araya T, Kita T, Kase K, Yamamura K, Terada N, Nishikawa S, Tambo Y, Kimura H, Kasahara K.
    Clin Lung Cancer; 2022 Sep 12; 23(6):467-476. PubMed ID: 35618628
    [Abstract] [Full Text] [Related]

  • 26. Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.
    Jahanzeb M, Lin HM, Pan X, Yin Y, Baumann P, Langer CJ.
    Clin Lung Cancer; 2021 Jan 12; 22(1):49-57. PubMed ID: 33250347
    [Abstract] [Full Text] [Related]

  • 27. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
    Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Ramaiya N, Presley CJ, Owen DH, Abou Alaiwi S, Nassar A, Ricciuti B, Lamberti G, Bersanelli M, Casartelli C, Buti S, Marchetti P, Giusti R, Filetti M, Vanella V, Mallardo D, Macherla S, Sussman TA, Botticelli A, Galetta D, Catino A, Pizzutilo P, Genova C, Dal Bello MG, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Choueiri TK, Johnson DB, Marron TU, Wang Y, Naqash AR.
    JAMA Oncol; 2021 Dec 01; 7(12):1856-1861. PubMed ID: 34734989
    [Abstract] [Full Text] [Related]

  • 28. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T, Yu M, Yu Y, Wang K, Tian P, Luo Z, Ding Z, Wang Y, Gong Y, Zhu J, Zou B, Sio TT, Alves A, Liu Y, Huang M, Lu Y.
    Transl Lung Cancer Res; 2022 Jun 01; 11(6):1027-1037. PubMed ID: 35832458
    [Abstract] [Full Text] [Related]

  • 29. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I, Mezquita L, Rossoni C, Auclin E, Kossai M, Aboubakar F, Le Moulec S, Massé J, Masson M, Radosevic-Robin N, Alemany P, Rouanne M, Bluthgen V, Hendriks L, Caramella C, Gazzah A, Planchard D, Pignon JP, Besse B, Adam J.
    Eur J Cancer; 2021 Mar 01; 145():221-229. PubMed ID: 33516050
    [Abstract] [Full Text] [Related]

  • 30. Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data.
    Nakahama K, Izumi M, Yoshimoto N, Fukui M, Sugimoto A, Nagamine H, Ogawa K, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T.
    Anticancer Res; 2023 May 01; 43(5):2185-2197. PubMed ID: 37097681
    [Abstract] [Full Text] [Related]

  • 31. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
    Lopes S, Pabst L, Dory A, Klotz M, Gourieux B, Michel B, Mascaux C.
    Front Immunol; 2023 May 01; 14():1070076. PubMed ID: 36776847
    [Abstract] [Full Text] [Related]

  • 32. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe H, Kubo T, Ninomiya K, Kudo K, Minami D, Murakami E, Ochi N, Ninomiya T, Harada D, Yasugi M, Ichihara E, Ohashi K, Fujiwara K, Hotta K, Tabata M, Maeda Y, Kiura K.
    Jpn J Clin Oncol; 2019 Aug 01; 49(8):762-765. PubMed ID: 31090906
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Non-small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect?
    Li Y, Gong B, Guo Y, Liu W, Chen C, Jiang S, Pan F, Song J, Yang L, Zhou G.
    BMC Cancer; 2024 Apr 27; 24(1):535. PubMed ID: 38671373
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H, Han KD, He ZJ, Huang YS.
    Technol Cancer Res Treat; 2021 Apr 27; 20():15330338211033498. PubMed ID: 34323149
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C, Li J, Zhang Q, Wu J, Xiao Y, Song L, Gong H, Li Y.
    BMC Cancer; 2021 Aug 28; 21(1):968. PubMed ID: 34454455
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K, Nakamura T, Abe T, Ogusu S, Nakashima C, Takahashi K, Kimura S, Sueoka-Aragane N.
    Thorac Cancer; 2019 Sep 28; 10(9):1798-1804. PubMed ID: 31328416
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.